Internal restructuring of foreign subsidiaries at Bliss GVS Pharma
Bliss GVS Pharma slipped 1.54% to Rs 74.03 after the company informed that the US FDA issued a Form 483 with 3 minor observations post the inspection conducted at its Palghar-based manufacturing facility.
Bliss GVS Pharma Limited is on FDA Import Alert List
Bliss GVS PharmaBSE 2.57 %'s Kenyan arm has won a three-year contract worth $111.40 million (around Rs 760 crore) from Aon Kenya Insurance Brokers.